Remove 2019 Remove Epilepsy Remove Patients Remove Safety
article thumbnail

Everything MMJ Patients Need To Know About Medical Marijuana Dispensaries in Texas

MMJ Recs

While the state has traditionally held a conservative stance on cannabis, there has been a gradual shift in public opinion and legislative action, paving the way for a more inclusive and patient-centric approach to healthcare. Additionally, patients must have exhausted all other available treatment options without finding relief.

article thumbnail

GW’s Cannabis-Based Epilepsy Drug Set For European Approval

Cannabis Law Report

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. GW Pharmaceuticals said in May, Epidiolex was successful in treating seizures in patients with a rare form of childhood epilepsy called tuberous sclerosis complex during a late-stage trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

article thumbnail

Tyson and Holyfield Announce Edibles, Texas’ Medical Cannabis Gains, and Big Hemp Study

Veriheal

Texas’ medical cannabis program is in the midst of a massive spike in patient registrations. According to the Texas Department of Public Safety Chief Wayne Muller, the state has averaged a 10% month-over-month increase in medical cannabis patients over the last 18 months. Let us know in the comments!

Edibles 97
article thumbnail

Thailand: Press Release Thailand Govt Pharma Organization “Pharmaceutical Organization, Department of Medical Cooperation, Research on Medical Marijuana Extracts For cancer patients with neurodegenerative epilepsy And nervous pain”

Cannabis Law Report

30 May 2019. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Google Translation. Today (30 May) at 09.30 Sick group 1.

article thumbnail

Cannabis laws in Texas

The Cannigma

In recent years, lawmakers have eased up on a number of cannabis-derived formulations, and since 2015, people with epilepsy can obtain cannabis oil that contains less than 0.5% THC are legal for use by qualifying medical patients. Patients do not need to register with the state or pay a fee to access the medical cannabis program.

Law 84
article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.